JP2019518798A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019518798A5 JP2019518798A5 JP2019519626A JP2019519626A JP2019518798A5 JP 2019518798 A5 JP2019518798 A5 JP 2019518798A5 JP 2019519626 A JP2019519626 A JP 2019519626A JP 2019519626 A JP2019519626 A JP 2019519626A JP 2019518798 A5 JP2019518798 A5 JP 2019518798A5
- Authority
- JP
- Japan
- Prior art keywords
- cdp
- pharmaceutical composition
- composition according
- dag
- choline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662355096P | 2016-06-27 | 2016-06-27 | |
| US62/355,096 | 2016-06-27 | ||
| PCT/US2017/039545 WO2018005527A1 (en) | 2016-06-27 | 2017-06-27 | Liponucleotide-based therapy for ards |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019518798A JP2019518798A (ja) | 2019-07-04 |
| JP2019518798A5 true JP2019518798A5 (enExample) | 2020-08-06 |
Family
ID=60786443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019519626A Pending JP2019518798A (ja) | 2016-06-27 | 2017-06-27 | リポヌクレオチドに基づくａｒｄｓの治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10874684B2 (enExample) |
| EP (2) | EP4292651A3 (enExample) |
| JP (1) | JP2019518798A (enExample) |
| KR (1) | KR20190022682A (enExample) |
| CN (1) | CN109475554A (enExample) |
| AU (1) | AU2017289278A1 (enExample) |
| CA (1) | CA3029005A1 (enExample) |
| SG (1) | SG11201811595SA (enExample) |
| WO (1) | WO2018005527A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4292651A3 (en) * | 2016-06-27 | 2024-03-13 | Ohio State Innovation Foundation | Liponucleotide-based therapy for ards |
| EP3645009A4 (en) * | 2017-06-27 | 2021-03-31 | The Ohio State Innovation Foundation | LIPONUCLEOTIDE THERAPY FOR COPD |
| EP4125857A4 (en) * | 2020-03-31 | 2024-04-17 | Diffusion Pharmaceuticals LLC | USE OF DIFFUSION ENHANCEMENT COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASE INDUCED BY VIRUSES AND BACTERIA |
| WO2021222535A1 (en) * | 2020-05-01 | 2021-11-04 | Irazu Bio | Method for treating respiratory viral infections comprising administration of fatty acid compositions |
| US20250177541A1 (en) * | 2022-03-11 | 2025-06-05 | Arizona Board Of Regents On Behalf Of Arizona State University | Pegylated serp-1 protein treatment improves outcomes after sars-cov-2 infection |
| WO2023177995A2 (en) * | 2022-03-18 | 2023-09-21 | Ohio State Innovation Foundation | Cdp-choline a host-directed therapeutic for disease caused by sars cov-2 infection |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4386078A (en) * | 1980-03-03 | 1983-05-31 | The Ohio State University Research Foundation | Therapeutic agents for preventing phospholipid degradation and free fatty acid proliferation |
| US5470838A (en) * | 1987-10-28 | 1995-11-28 | Pro-Neuron, Inc. | Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine |
| DE3883374T2 (de) * | 1987-10-28 | 1993-12-09 | Pro Neuron Inc | Acylatiertes uridin und cytidin und deren verwendungen. |
| AU712679B2 (en) * | 1994-07-01 | 1999-11-11 | Pro-Neuron, Inc. | Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis |
| US6825174B2 (en) * | 1995-06-07 | 2004-11-30 | East Carolina University | Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation |
| US20030181353A1 (en) * | 1998-08-03 | 2003-09-25 | Nyce Jonathan W. | Composition & use as analgesic, anti-inflammatory, wound healing agent, for treatment of heart conditions, assessment of heart function & tissue & cell protection & healing & reperfusion, mood disorders & symptoms & sequelae of menopause & for inducing unconsciousness, sleep & anesthesia |
| WO2006054304A2 (en) * | 2004-11-17 | 2006-05-26 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of lipid conjugates in the treatment of disease |
| US20040049022A1 (en) * | 2001-04-24 | 2004-03-11 | Nyce Jonathan W. | Composition & methods for treatment and screening |
| JP2004537544A (ja) * | 2001-07-13 | 2004-12-16 | パラテック ファーマシューティカルズ インコーポレイテッド | 標的治療活性を有するテトラサイクリン化合物 |
| US7084122B2 (en) * | 2001-11-21 | 2006-08-01 | Erik Larsen | Use of glycosides of mono- and diacyglycerol as anti-inflammatory agents |
| AU2006251562B2 (en) | 2005-05-23 | 2012-03-22 | Massachusetts Institute Of Technology | Compositions containing PUFA and methods of use thereof |
| CN101495490B (zh) * | 2005-05-23 | 2018-05-08 | 麻省理工学院 | 含有多不饱和脂肪酸和/或尿苷的组合物及其使用方法 |
| EP4292651A3 (en) * | 2016-06-27 | 2024-03-13 | Ohio State Innovation Foundation | Liponucleotide-based therapy for ards |
| EP3645009A4 (en) * | 2017-06-27 | 2021-03-31 | The Ohio State Innovation Foundation | LIPONUCLEOTIDE THERAPY FOR COPD |
| EP3645010A4 (en) * | 2017-06-27 | 2021-03-24 | Ohio State Innovation Foundation | NUCLEOTIDE-BASED THERAPY FOR ASTHMA |
-
2017
- 2017-06-27 EP EP23207788.3A patent/EP4292651A3/en active Pending
- 2017-06-27 KR KR1020197002042A patent/KR20190022682A/ko not_active Ceased
- 2017-06-27 CN CN201780039385.4A patent/CN109475554A/zh active Pending
- 2017-06-27 JP JP2019519626A patent/JP2019518798A/ja active Pending
- 2017-06-27 EP EP17821089.4A patent/EP3474853A4/en not_active Withdrawn
- 2017-06-27 SG SG11201811595SA patent/SG11201811595SA/en unknown
- 2017-06-27 AU AU2017289278A patent/AU2017289278A1/en not_active Abandoned
- 2017-06-27 WO PCT/US2017/039545 patent/WO2018005527A1/en not_active Ceased
- 2017-06-27 CA CA3029005A patent/CA3029005A1/en active Pending
-
2018
- 2018-12-21 US US16/230,225 patent/US10874684B2/en active Active
-
2020
- 2020-11-19 US US16/952,557 patent/US20210069225A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7786743B2 (ja) | ４’－ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用 | |
| JP2013518107A5 (enExample) | ||
| EP3356355B1 (en) | Compounds and combinations for the treatment of hiv | |
| TR201906470T4 (tr) | İmmünomodülatörler. | |
| Murugan et al. | COVID-19: A review of newly formed viral clades, pathophysiology, therapeutic strategies and current vaccination tasks | |
| US10874684B2 (en) | Liponucleotide-based therapy for ARDS | |
| CA2862755A1 (en) | Antiviral compounds with a dibenzooxaheterocycle moiety | |
| JP2010270130A5 (enExample) | ||
| JP2026027247A (ja) | ４’－ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用 | |
| WO2021211885A8 (en) | Matrix bound vesicles (mbv) for treatment of acute respiratory distress syndrome | |
| CN113164505A (zh) | 用于治疗丙型肝炎病毒的高活性药物组合 | |
| JP2009518410A5 (enExample) | ||
| JP2016533190A5 (enExample) | ||
| RU2012116226A (ru) | Бронхолитическое средство на основе простагландина | |
| JP6910043B2 (ja) | ヘマグルチニン結合ペプチド、および、これを含むインフルエンザウイルス感染症の予防・治療薬 | |
| Wang et al. | Discovery and Development of VV116: A Novel Oral Nucleoside Anti‐SARS‐CoV‐2 Drug | |
| JP2011016804A5 (enExample) | ||
| CN114948982A (zh) | 一种具有协同增效效应的药物组合物及其其抗病毒用途 | |
| JP2020521838A5 (enExample) | ||
| ZAREMBA et al. | TOXICITY OF POLYHYDRATED FULLERENES WITH ANTI-INFLUENZA ACTIVITY IN BOTH IN VITRO AND IN VIVO SYSTEMS | |
| RU2015144539A (ru) | Антибактериальные соединения против лекарственно-устойчивых бактерий | |
| HK40123809A (zh) | 含4'-卤素的核苷酸和核苷治疗组合物以及其相关用途 | |
| JP2023522628A5 (enExample) | ||
| Wang et al. | Anti HIV-1 agents 6. synthesis and anti-HIV-1 activity of indolyl glyoxamides | |
| HK40003888A (en) | Liponucleotide-based therapy for ards |